The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
作者： Hanne Fredly , Elisabeth Ersvær , Astrid Olsnes Kittang , Galina Tsykunova , Bjørn Tore Gjertsen
关键词: Comorbidity 、 Peripheral blood cell 、 Internal medicine 、 Immunology 、 Retinoic acid 、 Disease 、 Myeloid leukemia 、 Decitabine 、 Clofarabine 、 Medicine 、 Oncology 、 Valproic Acid
摘要: Background A large proportion of patients with acute myeloid leukemia (AML) are not fit for intensive and potentially curative therapy due to advanced age or comorbidity. Previous studies have demonstrated that a subset these can benefit from disease-stabilizing based on all-trans retinoic acid (ATRA) valproic acid. Even though complete hematological remission is only achieved exceptional patients, relatively respond this treatment stabilization normal peripheral blood cell counts.
biomedcentral.com
springer.com
core.ac.uk
paperity.org参考文章(63)
Pierre Fenaux, Claude Chastang, Sylvie Chevret, Miguel Sanz, Hervé Dombret, Eric Archimbaud, Martin Fey, Consuelo Rayon, Françoise Huguet, Jean-Jacques Sotto, Claude Gardin, Pascale Cony Makhoul, Philippe Travade, Eric Solary, Nathalie Fegueux, Dominique Bordessoule, Jesus San Miguel, Harmut Link, Bernard Desablens, Aspasia Stamatoullas, E. Deconinck, Fréderic Maloisel, Sylvie Castaigne, Claude Preudhomme, Laurent Degos, A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia Blood. ,vol. 94, pp. 1192- 1200 ,(1999) , 10.1182/BLOOD.V94.4.1192
Xavier Thomas, Amine Belhabri, [Acute myeloid leukemia in the elderly: a review]. Bulletin Du Cancer. ,vol. 88, pp. 143- 154 ,(2001)
Tapan M. Kadia, Hui Yang, Alessandra Ferrajoli, Sirisha Maddipotti, Claudia Schroeder, Timothy L. Madden, Julianne L. Holleran, Merrill J. Egorin, Farhad Ravandi, Deborah A. Thomas, Willie Newsome, Blanca Sanchez-Gonzalez, James A. Zwiebel, Igor Espinoza-Delgado, Hagop M. Kantarjian, Guillermo Garcia-Manero, A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia British Journal of Haematology. ,vol. 150, pp. 72- 82 ,(2010) , 10.1111/J.1365-2141.2010.08211.X
Emmanuel Raffoux, Audrey Cras, Christian Recher, Pierre-Yves Boëlle, Adrienne de Labarthe, Pascal Turlure, Jean-Pierre Marolleau, Oumedaly Reman, Claude Gardin, Maud Victor, Sébastien Maury, Philippe Rousselot, Jean-Valère Malfuson, Odile Maarek, Marie-Thérèse Daniel, Pierre Fenaux, Laurent Degos, Christine Chomienne, Sylvie Chevret, Hervé Dombret, Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome Oncotarget. ,vol. 1, pp. 34- 42 ,(2010) , 10.18632/ONCOTARGET.106
Stefan Faderl, Farhad Ravandi, Xuelin Huang, Xuemei Wang, Elias Jabbour, Guillermo Garcia-Manero, Tapan Kadia, Alessandra Ferrajoli, Marina Konopleva, Gautam Borthakur, Jan Burger, Jennie Feliu, Hagop M. Kantarjian, Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. ,vol. 118, pp. 4471- 4477 ,(2012) , 10.1002/CNCR.27429
Gesine Bug, Markus Ritter, Barbara Wassmann, Claudia Schoch, Thorsten Heinzel, Kerstin Schwarz, Annette Romanski, Oliver H. Kramer, Manuela Kampfmann, Dieter Hoelzer, Andreas Neubauer, Martin Ruthardt, Oliver G. Ottmann, Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer. ,vol. 104, pp. 2717- 2725 ,(2005) , 10.1002/CNCR.21589
Stefan Faderl, Farhad Ravandi, Xuelin Huang, Guillermo Garcia-Manero, Alessandra Ferrajoli, Zeev Estrov, Gautam Borthakur, Srdan Verstovsek, Deborah A. Thomas, Monica Kwari, Hagop M. Kantarjian, A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome Blood. ,vol. 112, pp. 1638- 1645 ,(2008) , 10.1182/BLOOD-2007-11-124602
Andres O. Soriano, Hui Yang, Stefan Faderl, Zeev Estrov, Francis Giles, Farhad Ravandi, Jorge Cortes, William G. Wierda, Souzanne Ouzounian, Andres Quezada, Sherry Pierce, Elihu H. Estey, Jean-Pierre J. Issa, Hagop M. Kantarjian, Guillermo Garcia-Manero, Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood. ,vol. 110, pp. 2302- 2308 ,(2007) , 10.1182/BLOOD-2007-03-078576
Anita Ryningen, Camilla Stapnes, Philippe Lassalle, Matthias Corbascio, Bjørn-Tore Gjertsen, Øystein Bruserud, A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leukemia Research. ,vol. 33, pp. 779- 787 ,(2009) , 10.1016/J.LEUKRES.2008.10.005
C. Wu, S. Wang, F. Wang, Q. Chen, S. Peng, Y. Zhang, J. Qian, J. Jin, H. Xu, Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clinical and Experimental Immunology. ,vol. 158, pp. 199- 204 ,(2009) , 10.1111/J.1365-2249.2009.04011.X